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Abstract
Background: C. difficile (CD) real-time polymerase chain reaction (PCR) for toxin B gene (tcdB) is more sensitive, and
reduces turnaround time when compared to toxin immunoassay. We noted typical amplification curves with high
tcdB cycle thresholds (Ct) and low endpoints (Ept) that are labeled negative by the Xpert® C. difficile assay (Cepheid)
and undertook this study to determine their significance.
Methods: We defined an indeterminate CD assay result as detection of a typical PCR amplification curve with an
Ept >10 that was interpreted as negative by the Xpert® assay. Samples with indeterminate Xpert® result were
collected for 5 months and retested by Xpert®, cultured for toxigenic CD, and isolates subjected to PCR ribotyping,
detection of toxin genes and multilocus variable-number tandem repeat analysis (MLVA) typing. Chart reviews were
completed to assess if patients met the Society of Healthcare Epidemiology of America and the Infectious Diseases
Society of America CD infection (CDI) clinical case definition. Illness severity was compared with tcdB Ct and culture
results.
Results: During the 5-month study period, 48/3620 (1%) of specimens were indeterminate and 387/3620 (11%)
were positive. Of the 48 patients with indeterminate results, 39 (81%) met the clinical case definition of CDI, and 7
of these (18%) met criteria for severe CDI. Toxigenic stool cultures were positive for 86% (6/7) of patients with
severe CDI, 19% (6/32) of patients with non-severe CDI, and 44% (4/9) of patients who did not meet the clinical
case definition of CDI (p = 0.002). Lower tcdB Ct and higher Ept were associated with greater likelihood of toxigenic
culture positivity (p = 0.03) and more severe symptoms (p = 0.06). Indeterminate results were not associated with a
particular technologist or instrument module, or CD strain type.
Conclusions: A subset of specimens (1%) using the Xpert® C. difficile assay have typical amplification curves and are
interpreted as negative. At least one-third of these results are associated with positive CD culture. The mechanism
of these indeterminate results is not technique-related, equipment-related, or due to particular CD strains. Clinicians
should be aware that even PCR testing has the potential to miss CDI cases and further highlights the importance of
clinical context when interpreting results.
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Background
Clostridium difficile is a significant nosocomial and
community-acquired pathogen associated with morbid-
ity, mortality and cost to the health-care system [1].
Diagnosis of Clostridium difficile infection (CDI) relies
on clinical manifestations of diarrhea, fever, abdominal
pain and leukocytosis, supported by laboratory confirm-
ation of toxigenic C. difficile in stool. C. difficile toxin
real-time polymerase chain reaction (PCR) is increas-
ingly being adopted in clinical laboratories because it is
more sensitive and reduces turnaround time when com-
pared to toxin immunoassay [2]. The Xpert® C. difficile
assay (Cepheid, Sunnyvale, CA) is a real-time random-
access PCR assay which detects the toxin B gene (tcdB).
It has a sensitivity of 93.5-100% and specificity of 94.0-
97.9% compared with toxigenic culture [2-5].
According to the product monograph, the amplifica-
tion curve of the Xpert® C. difficile assay must have a
cycle threshold within a valid range and endpoint above
a set minimum to be considered positive for tcdB. Dur-
ing our evaluation of this assay, we noticed typical amp-
lification curves for some specimens that had high cycle
thresholds and low endpoints, which were interpreted as
negative by the Xpert® assay. We undertook the follow-
ing quality assurance study to investigate the clinical and
microbiologic significance of these results.
Methods
Setting and study design
In January 2011, real-time PCR assay for detection of C.
difficile toxin B (Cepheid GeneXpert System, Sunnyvale,
CA) was introduced at the University Health Network/
Mount Sinai Hospital Department of Microbiology clin-
ical laboratory in Toronto, Canada. This laboratory ser-
vices six acute care hospitals, three inpatient rehabilitation
centres and one hospital providing complex care.
Definitions
We defined an indeterminate Xpert® C. difficile assay re-
sult as detection of a typical PCR amplification curve
with an endpoint >10 that was interpreted as negative by
Xpert®. Between January 5 and May 18, 2011, all non-
duplicate Xpert® C. difficile assay results that displayed
an indeterminate result were included in the study.
Clinical data collection
Infection prevention and control records and patient
medical records were reviewed to determine whether pa-
tients with indeterminate results met the clinical case
definition of CDI as defined by the Society of Healthcare
Epidemiology of America and the Infectious Diseases So-
ciety of America (SHEA/IDSA) [6]. To meet this case def-
inition, patients required passage of three or more
unformed stools in less than 24 hours that was not due to
an alternate cause. Patients were classified as having se-
vere disease if they had a score of ≥2 points where 1 point
each was given for age >60 years, temperature >38.3°C,
serum albumin <25 g/L, or peripheral white blood cell
count >15.0 × 109/L, and 2 points were given for endo-
scopic evidence of pseudomembranous colitis or require-
ment for intensive care unit admission [7]. If same-day
blood results were not available, results from blood sam-
ples obtained within 48 hours of the stool specimen were
accepted. Outcomes assessed included the need for inten-
sive care unit admission or colectomy due to the CDI epi-
sode and patient status at 30 days (deceased, alive in
hospital or discharged from hospital).
Microbiologic studies
Laboratory records were reviewed to identify whether in-
determinate results were associated with a particular tech-
nologist or a particular instrument module. Each stool
specimen with an indeterminate result was planted onto
C. difficile moxalactam-norfloxacin agar, with toxigenicity
of isolated C. difficile confirmed by a laboratory-derived
tcdB PCR assay [8,9]. Each indeterminate specimen was
subjected to repeat PCR testing using Xpert® on an aliquot
of frozen (−80°C) stool to assess whether repeat testing of
indeterminate results could improve detection of C. diffi-
cile compared with toxigenic culture.
To determine whether indeterminate results were as-
sociated with a particular C. difficile strain, toxigenic
culture isolates were subjected to PCR ribotyping, toxin
genotyping and multilocus variable-number tandem re-
peat analysis (MLVA) typing as previously described
[8,9]. Ribotypes were identified using http://webribo.
ages.at/ [10] and data analysed using BioNumerics soft-
ware v.6.6 (Applied Maths, Austin, TX, U.S.A).
Statistical methods
Data were analyzed using Microsoft Excel, version 11.0,
to provide descriptive statistics related to the incidence
of indeterminate C. difficile results and the presence of
CDI based on our preselected clinical criteria. Statistical
analysis was performed using Chi-squared or Fisher’s
exact tests using GraphPad software Inc., to assess the
statistical significance of differences in proportions.
Ethics
Approval from the local research ethics board was
waived because the clinical isolates were obtained as part
of standard care and the project was conducted for
microbiology quality assurance purposes.
Results
During the 5-month study period, 48 of 3620 (1%) of
specimens were indeterminate and 387 of 3620 (11%)
were positive. All indeterminate results were associated
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with inpatient admissions or emergency visits and oc-
curred throughout the ten health care facilities serviced
by the laboratory. They were not associated with one
technologist or one instrument module.
Clinical features
Thirty-nine of 48 patients (81%) with indeterminate results
met the clinical criteria for CDI while 9 (19%) patients had
less than three bowel movements within 24 hours or had
an obvious alternate cause for diarrhea such as a flare of
inflammatory bowel disease, another bacterial cause of
diarrhea or laxative use.
Of those who met the clinical case definition of CDI,
the median age was 72 years (18–93 years), 21 (54%)
were female, 4 (10%) had fever (T ≥ 38.3°C), 4 (10%)
had leukocytosis (WBC >15.0 × 109/L), 8 (21%) had
hypoalbuminemia (< 25 g/L), and 5 (13%) had acute
kidney injury (serum creatinine >1.5 × baseline). Seven
(18%) patients met our criteria for severe disease; none
suffered a CDI-related complication. Three patients
(all with non-severe disease) underwent endoscopy;
none had evidence of pseudomembranous colitis. Six pa-
tients who met CDI clinical criteria had a documented
positive tcdB result using Xpert® within 30-days of the in-
determinate result; three of these occurred before and
three after the indeterminate result.
In terms of therapy, 24/39 (62%) received oral metro-
nidazole, 3/39 (8%) received oral vancomycin, 6 (15%) re-
ceived both oral vancomycin plus oral or intravenous
metronidazole, and 6 (15%) received no therapy. There was
no difference between patients in each treatment group in
terms of disease severity or toxigenic culture-positivity.
Microbiologic studies
Sixteen of the 48 samples (33%) with indeterminate re-
sults yielded toxigenic C. difficile in culture. Stool speci-
mens from 6 of the 7 patients (86%) with severe CDI
were positive by toxigenic stool culture compared with 6
of 32 patients (19%) with CDI who did not meet criteria
for severe disease and 4 of 9 patients (44%) who did not
have CDI by clinical criteria (P = 0.002).
As demonstrated in Table 1, lower cycle thresholds
were associated with a greater likelihood of toxigenic
culture positivity (P = 0.03) and more severe clinical dis-
ease (P = 0.06). Repeat testing of indeterminate speci-
mens resulted in conversion to negative in 51% of cases
and positive in 20% of cases (Table 2). Culture-positive
specimens were more likely to be positive on repeat test-
ing compared to culture-negative specimens (P = 0.03).
Results of ribotyping and MLVA revealed that indeter-
minate results were not associated with a particular
C. difficile strain (Figure 1).
Discussion
The Xpert® C. difficile assay is a highly sensitive real-
time random-access PCR assay. We describe a subset of
clinical stool specimens (~1%) with indeterminate results
for tcdB which may be clinically significant. Indeed, one-
third had toxigenic C. difficile culture confirmation and
over 80% met the SHEA/IDSA clinical case definition of
C. difficile infection, 18% of whom had features of severe
infection. We cannot rule out that some of these pa-
tients may have been colonized with low levels of C. dif-
ficile while having another cause for their diarrhea other
than C. difficile that was not identified by their care pro-
viders. Previous published work has emphasized the high
sensitivity of PCR for C. difficile toxin B detection and
the potential to over-diagnose CDI when interpreting C.
difficile PCR results without considering clinical data
[11-14]. This study emphasizes that clinicians should be
aware that even PCR testing has the potential to miss
CDI cases on rare occasions and further highlights the
importance of clinical context when interpreting test
results.
The observation that toxigenic C. difficile may be
present at or below the limit of detection of the Xpert®
C. difficile assay has recently been noted in a study
evaluating its use for detection of environmental con-
tamination [15]. In this study, only one-third of environ-
mental specimens positive by toxigenic C. difficile
culture were detectable as positive by the Xpert® C. diffi-
cile assay. Our results suggest that low levels of C. diffi-
cile may also be present in vivo that fall below the level
of detection of PCR.
The mechanism of these indeterminate results is not
technique-related, equipment-related, or due to particular
Table 1 Proportions (%) of stool specimens with indeterminate Xpert® C. difficile assay results that yielded toxin-






results (n = 48)
Patients who did not meet
the C. difficile infection
clinical case definition (n = 9)
Patients who met the C. difficile
infection clinical case definition with
non-severe clinical disease (n = 32)
Patients who met the C. difficile
infection clinical case definition
with severe clinical disease (n = 7)
37.1-37.9 6/11 (55) 0/2 (0) 1/4 (25) 5/5 (100)
38.0-38.9 6/16 (38) 1/3 (33) 4/11 (36) 1/2 (50)
39.0-30.9 3/16 (19) 2/3 (67) 1/13 (8) 0
≥40 1/5 (20) 1/1 (100) 0/4 (0) 0
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C. difficile strains. Other potential factors that could con-
tribute to indeterminate results, but were not specifically
evaluated by this study, include the timing of therapy for
C. difficile in relation to testing and the presence of PCR
interfering substances in stool. Sunkesula et al. recently
showed that in a cohort of 51 PCR confirmed CDI patients
on treatment, 14% of patients had converted to negative
PCR within 24 hours, which increased to 35% of patients at
48 hours [16]. Any significant delay in obtaining a patient
specimen following initiation of therapy could contribute to
a false-negative tcdB by PCR [16,17].
It is worth considering whether indeterminate results
should be routinely reported by the microbiology labora-
tory, or whether this information could be used to im-
prove performance characteristics of the Xpert® C. difficile
assay. Changing the instrument’s threshold for reporting
positives could increase sensitivity but at the cost of speci-
ficity. Repeat testing of indeterminate specimens would be
associated with increased cost and may not significantly
improve performance characteristics as it produced mixed
results in our cohort. Although culture-positive specimens
were more likely to be positive on repeat testing, two pa-
tients who converted to negative were culture-positive
and had severe disease. Given these limitations, our insti-
tution currently reports all specimens that are negative by
the Xpert® assay but have typical amplification curves with
endpoints >10 as indeterminate, with a report that recom-
mends interpretation based on the clinical context. These
patients are assessed by infection control practitioners and
contact precautions are enforced for those patients with
clinically significant diarrhea.
This study has several important limitations including
its small sample size and retrospective design. We ap-
plied pre-selected published criteria to determine disease
severity but many features including leukocytosis and
hypoalbuminemia are not specific for CDI and may be
present in acutely ill patients for a variety of reasons.
We did, however, use infection prevention and control
records and patient medical records to determine
whether patients had clinically significant diarrhea, and
those with alternate causes for their symptoms based on
available clinical and microbiologic data, were excluded.
Table 2 Results of repeat Xpert® C. difficile testing of indeterminate specimens for all specimens, culture-positive
specimens, and specimens from patients with severe disease




Repeat test of culture-positive
specimens (N (%))
Repeat test of specimens from
patients with severe CDI (N (%))
Negative 0 (0) 23/45 (51) 2/14 (14) 2/7 (29)
Indeterminate* 48 (100) 13/45 (29) 7/14 (50) 2/7 (29)
Positive 0 (0) 9/45 (20) 5/14 (36) 3/7 (43)
* These results were interpreted as negative by the Xpert® assay but had typical amplification curves with a high cycle threshold and low endpoint.
†Three samples did not have sufficient quantity of stool to repeat testing.
Figure 1 Ribotyping and multiple loci variable-number tandem-repeat analysis (MLVA) results for C. difficile isolated from stool
specimens with indeterminate Xpert® C. difficile assay results. % similarity was calculated using ribotyping and MLVA composite data sets
using the unweighted pair group method with arithmetic mean. rel = related.
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Another limitation is that we did not account for the
timing of therapy for C. difficile in relation to testing,
which may have played a role in producing indetermin-
ate results [16,17]. Further work is needed to better
understand the mechanism of indeterminate PCR re-
sults, their clinical importance and their potential role in
hospital transmission.
Conclusions
A subset of stool specimens (1%) using the Xpert® C. difficile
assay have typical amplification curves and are interpreted
as negative. At least one-third of these results are associated
with positive CD culture. Our study, while limited by its
small sample size and retrospective design, emphasizes that
clinicians should be aware that even PCR testing has the po-
tential to miss CDI cases and further highlights the import-
ance of clinical context when interpreting results.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
All authors contributed significantly to this manuscript. SH, AM, JN and SMP
were involved in the conception of the project, data analysis and editing of
the manuscript. JAL undertook the chart review, data analysis and drafted
the manuscript. WLG was involved in the data analysis and contributed
significantly to the editing of the manuscript. DP and GB performed
toxigenic stool testing, PCR-ribotyping and multiple-locus variable number
tandem repeat analysis, and both edited the manuscript. PR and ZH were
involved in retrieving infection control records of patients and edited the
manuscript. All authors approved the final version of the manuscript.
Acknowledgements
We thank Inter Medico (Markham, ON) for the provision of supplies and
Gianna Zecchini from Inter Medico (Markham, ON) for her expertise and
technical support related to reproducibility testing.
Author details
1Division of Infectious Diseases, Department of Medicine, University Health
Network/Mount Sinai Hospital, Toronto, ON, Canada. 2Division of Infectious
Diseases, Department of Medicine, University of Toronto, Toronto, ON,
Canada. 3Department of Microbiology, University Health Network/Mount
Sinai Hospital, Toronto, ON, Canada. 4Bridgepoint Hospital, Toronto, ON,
Canada. 5Division of Medical Microbiology, Department of Laboratory
Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
6Public Health Ontario, Toronto, ON, Canada. 7Rouge Valley Health System,
Toronto, ON, Canada. 8Current address: Calgary Lab Services and Department
of Pathology and Laboratory and Medicine, University of Calgary, Calgary, AB,
Canada.
Received: 20 January 2013 Accepted: 8 July 2013
Published: 16 July 2013
References
1. Poutanen SM, Simor AE: Clostridium difficile-associated diarrhea in adults.
CMAJ 2004, 171(1):51–58.
2. Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T,
Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV,
Akerlund T, Weissfeld AS, Baron EJ, Wong E, Marlowe EM, Whitmore J,
Persing DH: Impact of strain type on detection of toxigenic Clostridium
difficile: comparison of molecular diagnostic and enzyme immunoassay
approaches. J Clin Microbiol 2010, 48(10):3719–3724.
3. Viala C, Le Monnier A, Maatoaoui N, Rousseau C, Colignon A, Poilane I:
Comparison of commercial molecular assays for toxigenic Clostridium
difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and
illumigene C. difficile. J Microbiol Methods 2012, 90(2):83–85.
4. Zidarič V, Kevorkijan BK, Oresic N, Janezic S, Rupnik M: Comparison of two
commercial molecular tests for the detection of Clostridium difficile in the
routine diagnostic laboratory. J Med Microbiol 2011, 60(Pt 8):1131–1136.
5. Shin S, Kim M, Kim M, Lim H, Kim H, Lee K, Chong Y: Evaluation of the
Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile
infection. Ann Lab Med 2012, 32(5):355–358.
6. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J,
Wilcox MH: Clinical practice guidelines for Clostridium difficile Infection
in Adults: 2010 update by the Society for Healthcare Epidemiology of
America (SHEA) and the Infectious Diseases Society of America (IDSA).
Infect Control Hosp Epidemiol 2010, 31(5):431–455.
7. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A comparison of
vancomycin and metronidazole for the treatment of Clostridium difficile-
associated diarrhea, stratified by disease severity. Clin Infect Dis 2007,
45(3):302–307.
8. Arroyo LG, Rousseau J, Willey BM, Low DE, Staempfli H, McGeer A, Weese JS:
Use of selective enrichment broth to recover Clostridium difficile from
stool swabs stored under different conditions. J Clin Microbiol 2005,
43(10):5341–5343.
9. Broukhanski G, Low DE, Pillai DR: Modified multiple-locus variable-number
tandem-repeat analysis for rapid identification and typing of Clostridium
difficile during institutional outbreaks. J Clin Microbiol 2011, 49(5):1983–1986.
10. Indra A, Huhulesu S, Schneeweis M, Hasenberger P, Kernbichler S, Fiedler A,
Wewalka G, Allerberger F, Kuijper EJ: Characterization of Clostridium
difficile isolates using capillary gel electrophoresis-based PCR ribotpying.
J Med Microbiol 2008, 57(Pt11):1377–1382.
11. Huang H, Weintraub A, Fang H, Nord CE: Comparison of a commercial
multiplex real-time PCR to the cell cytotoxicity neutralization assay
for diagnosis of clostridium difficile infections. J Clin Microbiol 2009,
47(11):3729–3731.
12. Goldenberg SD, Dieringer T, French GL: Detection of toxigenic Clostridium
difficile in diarrheal stools by rapid real-time polymerase chain reaction.
Diagn Microbiol Infect Dis 2010, 67(3):304–307.
13. Peterson LR, Manson RU, Paule SM, Hacek DM, Robicsek A, Thomson RB Jr,
Kaul KL: Detection of toxigenic Clostridium difficile in stool samples by
real-time polymerase chain reaction for the diagnosis of C. difficile-
associated diarrhea. Clin Infect Dis 2007, 45(9):1152–1160.
14. Dubberke ER, Han Z, Bobo L, Hink T, Lawrence B, Copper S, Hoppe-Bauer J,
Burnham CA, Dunne WM Jr: Impact of clinical symptoms on
interpretation of diagnostic assays for Clostridium difficile infections.
J Clin Microbiol 2011, 49(8):2887–2893.
15. Deshpande A, Cadnum J, Sitz Lar B, Kundrapu S, Donskey C: Evaluation of a
Commercial PCR Assay for Detection of Environmental Contamination with
Clostridium difficile. San Diego, CA: ID week, Epidemiology and Infection
Control. [2012 Oct 18; cited 2013 Jan 10]. Poster number 327 (Session
number 51) available from: https://idsa.confex.com/idsa/2012/
viewsessionpdf.cgi.
16. Sunkesula VC, Kundrapu S, Muganda C, Sethi AK, Donskey CJ: Does
empirical Clostridium difficile Infection (CDI) Therapy Result in False-
Negative CDI Diagnostic Test Results? Clin Infect Dis. E-published ahead of
print (accessed June 27, 2013).
17. Donskey CJ, Sethi AK, Sunkesula VC, Sitzlar B, Jury LA, Kundrapu S: Easily
modified factors contribute to delays in diagnosis of Clostridium difficile
Infection: a Cohort Study and Intervention. J Clin Microbiol 2013.
E-published ahead of print (accessed June 27, 2013).
doi:10.1186/1471-2334-13-324
Cite this article as: Leis et al.: Indeterminate tcdB using a Clostridium
difficile PCR assay: a retrospective cohort study. BMC Infectious Diseases
2013 13:324.
Leis et al. BMC Infectious Diseases 2013, 13:324 Page 5 of 5
http://www.biomedcentral.com/1471-2334/13/324
